Volume 16, Number 18,
Issue of September 15, 1996
pp. 5741-5748
Copyright ©1996 Society for Neuroscience
Modulation of the Inhibitory Substrate Properties of
Oligodendrocytes by Platelet-Derived Growth Factor
Received May 7, 1996; revised June 21, 1996; accepted June 28, 1996.
Dirk M. Lang1,
Michael
G. Hille1,
Martin E. Schwab2, and
Claudia A. O. Stuermer1
1 Faculty of Biology, University of Konstanz, D-78434
Konstanz, Germany, and 2 Institute for Brain Research,
University of Zürich, CH-8029 Zürich, Switzerland
Although growth cones typically collapse after encountering
O1/galactocerebroside (GalC)-positive oligodendrocytes, the majority of
growth cones traversed oligodendrocytes, which were raised for 8-10 d
in medium containing 10 ng/ml platelet-derived growth factor (PDGF).
Oligodendrocytes raised 8-10 d in control medium caused growth cone
collapse as they normally do, but failed to elicit this response after
being transferred to PDGF-containing medium for an additional 8-10 d.
The opposite was observed when PDGF-treated oligodendrocytes were
brought to control medium. Growth cones collapsed when contacting these
cells. Oligodendrocytes also lost their collapse-inducing activity when
raised in medium conditioned by astrocytes, known to produce PDGF.
Antibody IN-1 is directed against neurite growth inhibitors (NI),
proteins of 35 and 250 kDa on the surface of O1/GalC-positive
oligodendrocytes, which are known to elicit growth cone collapse. IN-1
immunoreactivity was markedly reduced in PDGF-treated oligodendrocytes.
However, both PDGF-treated and control oligodendrocytes exhibited
myelin-associated glycoprotein, proteolipid protein, and myelin basic
protein immunoreactivity. This suggests that PDGF-treatment affects NI
expression but does not interfere with the expression of advanced
myelin marker proteins. Because NI cause growth cone collapse, the loss
of collapse-inducing activity by PDGF-treated oligodendrocytes suggests
that PDGF regulates, directly or indirectly, the expression of these
proteins.
Key words:
oligodendrocyte;
loss of inhibitory
properties;
PDGF-treatment;
growth cone collapse;
IN-1
immunoreactivity;
astrocyte-conditioned medium